By Robb M. Stewart

 

Rubius Therapeutics Inc. Thursday named Dannielle Appelhans as chief operating officer to oversee corporate strategy and technical operations.

The appointment is effective Aug. 9, the clinical-stage biopharmaceutical company said.

Most recently, Ms. Appelhans was senior vice president of technical operations and chief technical officer at Novartis Gene Therapies, where she oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio Rubius. Prior to joining Novartis, she was a senior engagement manager at McKinsey & Co. in its pharmaceutical operations practice, and earlier in her career she held roles at Eli Lilly & Co.

 

Write to Robb M. Stewart at robb.stewart@wsj.com

 

(END) Dow Jones Newswires

July 29, 2021 09:06 ET (13:06 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Novartis Charts.